Cellectar Biosciences EBIT Margin

What does Cellectar Biosciences do? Cellectar Biosciences develops phospholipid drug conjugates (PDCs) for cancer treatment and imaging, focusing on targeted delivery to cancer cells. The company's pipeline includes CLR 131, a radiotherapeutic PDC using iodine-131 for targeted cancer cell treatment, and CLR 1900, a preclinical chemotherapeutic PDC targeting solid tumors by inhibiting mitosis. These products are developed through the company's PDC cancer-targeting delivery platform, which aims to limit exposure to healthy cells while delivering therapeutic payloads directly to cancer cells. The company's revenue model relies on the development and potential commercialization of its PDC-based therapies, with CLR 131 in clinical stages and CLR 1900 in preclinical development. As a biopharmaceutical company, Cellectar Biosciences generates income through research and development activities, including clinical trials and preclinical studies, to advance its product candidates toward regulatory approval and market entry. Cellectar Biosciences targets cancer patients requiring targeted therapies, particularly those with solid tumors where mitosis inhibition is a validated treatment approach. The company's focus on PDC technology positions it to address unmet medical needs in oncology, with potential partnerships or licensing agreements for its pipeline products to support future revenue streams. Cellectar Biosciences is one of the most popular companies on Eulerpool.